The App That Treats Schizophrenia Just Lost 27% of Its Team

Fire, Then Hire?

Chief Strategy Officer Austin Speier described the restructuring as a "natural transition point." The company confirmed it cut 27% of its workforce, though it didn't disclose exact headcount. Speier said Click plans to hire commercial roles to support the launch, suggesting the layoffs were about swapping out R&D-heavy staff for salespeople and market-access specialists.

It's a move that makes strategic sense on paper. You don't need the same team to sell an app that you needed to build it. But the optics are rough: announcing a $50 million raise and layoffs in the same week is the corporate equivalent of posting vacation photos while calling in sick.

The Ghost of Pear Therapeutics

Click's pivot comes with a warning label, and its name is Pear Therapeutics.

Pear was the poster child of prescription digital therapeutics. It had FDA-cleared products, big funding rounds, and a compelling narrative about software replacing pills. Then it filed for bankruptcy in 2023. The problem wasn't the science; it was everything around it. Insurance companies didn't know how to reimburse apps. Doctors didn't know how to prescribe them. Patients didn't stick with them long enough to see benefits.

Pear's collapse sent shockwaves through the entire category. Companies merged, pivoted, or quietly shut down. Click actually acquired some of Pear's assets in the aftermath, picking through the wreckage for useful pieces.

Now Click is attempting what Pear couldn't pull off: turning a prescription digital therapeutic into a viable commercial product. The stakes are enormous, not just for Click, but for the entire idea that software can be medicine.

The Reimbursement Puzzle (Still Missing Pieces)

The biggest question hanging over Click isn't whether CT-155 works. The clinical data already answered that. The question is whether anyone will pay for it.

Prescription digital therapeutics exist in a reimbursement gray zone. Traditional drugs have well-worn pathways through insurance formularies and pharmacy benefit managers. An app that treats schizophrenia? Not so much. CMS introduced new billing codes for FDA-cleared digital therapeutics in 2025, which was a step forward. But coverage remains patchy, and convincing payers to reimburse software the same way they reimburse a pill requires proving the economic case over and over again.

The difference between a market forecast and actual revenue is, well, a bankruptcy filing.

Experts say the companies that survive in this space will be the ones tying outcomes directly to cost savings: proving that their products reduce hospitalizations, improve medication adherence, and lower the total cost of care. Click will need to make that case convincingly, and quickly.

A Broader Industry Pattern

Click isn't alone in trimming headcount. The first quarter of 2026 saw 33 biopharma companies announce layoffs or shutdowns, though the pace has slowed compared to 2025's bloodbath. Astellas cut 55 jobs at its Seattle stem cell unit. Replimune shed 63 roles after the FDA rejected its melanoma drug. Evotec announced 800 job cuts across all its sites over two years, closing four of them.

The common thread? Companies hitting inflection points (clinical failures, commercial pivots, post-acquisition integration) and realizing their workforce doesn't match their new reality. Click fits neatly into that pattern, even if its specific challenge is unique.

What Comes Next

Click Therapeutics is now a company in transition. It has strong clinical data, FDA fast-track status, and $50 million in fresh capital. It also has a smaller team, a category with a checkered commercial history, and the daunting task of convincing hospitals, insurers, and patients that downloading an app is a legitimate treatment for one of psychiatry's most challenging conditions.

The prescription digital therapeutics space needs a success story. It needs proof that the Pear Therapeutics outcome was a cautionary tale, not a prophecy. Click has the best shot anyone's had in years. Whether the company can convert that opportunity into revenue will determine not just its own fate, but whether "software as medicine" remains a viable category or becomes a footnote in biotech's long history of good ideas that couldn't find a business model.